The Official Journal of the Turkish Society Of Clinical Microbiology and Infectious Diseases (KLİMİK)

Treatment

Filter Newest Oldest Showing 1-8 of 8 results
Case Report / VOLUME 2, ISSUE 1, APRIL 2020

Adverse Cardiac Events Related to Hydroxychloroquine Prophylaxis and Treatment of COVID-19

Rehile Zengin and others

Hydroxychloroquine is commonly used for the treatment of rheumatic diseases because of its antinflammatory effects. It is a 4-amino-quinoline that is widely used for the treatment purposes. The Scientific Advisory Board of Ministry of Health of Turkey for COVID-19 recommends HCQ for treatment and also for prophylactic use of COVID-19. Infectious Diseases Society of America (IDSA) suggested the HCQ but also warned Read More

Original Article / VOLUME 4, ISSUE 4, DECEMBER 2022

Stenotrophomonas maltophilia Bacteremia: From Diagnosis to Treatment

Pınar Aysert-Yıldız and others

Stenotrophomonas maltophilia is an aerobic, non-fermentative, Gram-negative bacterium widespread in aquatic environments and soil. It has an inherent ability to adhere to abiotic surfaces and forms biofilms. It is usually considered to be a commensal and a low-grade pathogen. However, it can cause severe infections in the immunocompromised and debilitated (...) Read More

Original Article / VOLUME 5, ISSUE 2, JUNE 2023

COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study

Özge Kaya and others

Psoriasis, a chronic inflammatory disease, has a multifactorial etiology, including genetic, environmental, and behavioral factors. Since psoriasis is an immune system-mediated disease, immunosuppressive agents and biological treatments are frequently used in its treatment; however, these agents are known to increase the risk of infection. This situation (...) Read More

Review Article / VOLUME 5, ISSUE 3, SEPTEMBER 2023

COVID-19: An Update on Epidemiology, Prevention and Treatment, September-2023

Serap Şimşek-Yavuz

After the World Health Organization (WHO) declared an end to COVID-19 as a global public health emergency on May 5, 2023, we have entered a new era in the pandemic, and most countries have already returned to normal life. This declaration was resulted from the 12-month downward trend of the pandemic, increased immunity due to the highly effective vaccines, decreased death rates, and decreased pressure on once overwhelmed (...) Read More

Review Article / VOLUME 5, ISSUE 4, DECEMBER 2023

New Treatment Options in Chronic Hepatitis B: How Close Are We to Cure?

Pınar Korkmaz and others

Hepatitis B virus (HBV) infection is the leading cause of chronic liver disease worldwide. HBV-infected patients are at risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) for life. Today, pegylated interferon (Peg-IFN) and nucleos(t)ide analogues (NAs) are used in the treatment of patients with chronic hepatitis B (CHB). Both treatment options have limitations. Read More